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Introduction JPET #156398 5 element binding protein (CREB) and inhibition of protein kinase A (PKA) activity (Fujino et al., 2003; Fujino et al., 2005) . Moreover, activation of EP 4 by PGE 2 leads to rapid desensitization (Nishigaki et al., 1996) , as well as recruitment of ß-arrestins 1 and 2 and internalization of the receptor (Desai and Ashby, 2001) . Accumulating evidence indicates that ß-arrestins can also serve as scaffolds to activate signaling cascades independently of G protein coupling for many GPCRs (DeWire et al., 2007) . This was shown to be the case for EP 4 in colorectal cancer cells, where ß-arrestin 1-dependent c-Src activation, and not G-protein activation, is responsible for PGE 2 /EP 4 -mediated increased cellular migration and metastasis (Buchanan et al., 2006) . Therefore, specific subsets of EP 4 signaling are involved in the clinically relevant effects of PGE 2 .
Growing evidence suggests that GPCRs can exist in multiple active conformations (Kenakin, 2003) . Different ligands can stabilize distinct active receptor conformations that are only permissive to a subset of the receptor's complete repertoire of behaviors, or activate distinct pathways with different potency and intrinsic activity (efficacy). Thus, individual agonists lead to differential and independent coupling of the receptor to different G proteins or intracellular effectors, a concept referred to as functional selectivity (Galandrin et al., 2007; Urban et al., 2007) . To date, prostanoid receptor ligands are mainly characterized by their relative binding affinity to the different receptor subtypes as determined by radioligand competition binding assays (Abramovitz et al., 2000; Davis and Sharif, 2000) . The evaluation of the functional JPET #156398 6 will be relevant for their use as pharmacological tools, with potential clinical relevance (Buchanan et al., 2006) .
In this study, we use three different BRET assays for functional pharmacological characterization of various EP 4 receptor ligands in living HEK293 cells by evaluating the relative potency and intrinsic activity of these ligands on three distinct signaling pathways relevant for EP 4 biology, namely the activation of Gα i and Gα s subunits, as well as the recruitment of ß-arrestin.
JPET #156398 KLPAT-Rluc3 in pCDNA3.1/Zeo. Finally, the substitutions T781A and F782A were introduced by PCR to remove the Rap1 binding site of Epac1. YFP-Gβ 1 expression vector was obtained from GFP10-Gβ 1 (Galés et al., 2005) by replacing GFP10 with the coding sequence of eYFP (pIRES-eYFP, Clontech) . Plasmids encoding Gα i1 -91Rluc and Rluc-ß-arrestin 2 have been described previously (Perroy et al., 2003; Galés et al., 2006) . All generated constructs were confirmed by sequencing. added at a final concentration of 5µM in BRET buffer (PBS, 0.5 mM MgCl 2 , 0.1% glucose).
BRET readings were collected using a Mithras LB940 plate reader (Berthold) and (Fig. 1B) ; stimulation of cells with a saturating (1 μM) dose of PGE 2 indicated that the maximal PGE 2 -induced response was within the linear range of the Epac sensor response. The cAMP levels induced by PGE 2 stimulation rose rapidly and peaked after ~5-10 minutes, after which they slowly decreased due to the action of phosphodiesterases and the desensitization of the receptor and cAMP production system (Fig. 1C) . To make certain that the measured BRET 2 signal was specific to EP 4 receptor activation, we pre-treated cells with the EP 4 -specific antagonist GW627368X; this resulted in abrogation of the PGE 2 -mediated cAMP level increase (Fig. 1D) . A This article has not been copyedited and formatted. The final version may differ from this version. (Galés et al., 2006) . Specifically, the Rluc donor was inserted within the loop connecting helices A and B of the Gα i helical domain, and the YFP acceptor was fused to the N-terminus of Gß 1 . Under basal conditions, a strong BRET signal between Gα i1 -Rluc and YFP-Gß 1 was measured ( Fig. 2A) , indicative of pre-association of Gα i1 and Gß 1 . Kinetic analysis of the BRET signal upon stimulation of EP 4 by PGE 2 , but not vehicle alone ( Fig. 2A, inset), revealed a very rapid decrease in the BRET signal (within 1s); this decrease was sustained for at least 3 minutes. This signal was dose-dependent, with an average EC 50 of 4.08 nM (Table 1 and Fig. 2B ). No response was detected in cells pre-treated with PTX or the EP 4 antagonist GW627368X, or in cells in which empty vector was co-transfected in place of EP 4 (Fig. 2C ), activation has been used for a multitude of GPCRs, and has also been used as a high throughput screening method for the identification of ligands (Hamdan et al., 2005) . Fusion of YFP at the Cterminus of EP 4 had no effect on binding affinity of to PGE 2 resulted in a significant concentration-dependent increase in the BRET signal detected over basal level ( Fig. 3B) , with an average EC 50 of 2.01 nM (Table 1) . PGE 2 -induced recruitment of Rluc-ß-arrestin 1 to EP 4 -YFP showed similar kinetics and potency as for ß-arrestin 2 (data not shown). Pre-treatment of cells with PTX had no effect on the PGE 2 -induced recruitment of ß-arrestin 1 or 2 to EP 4 (results not shown), suggesting that this process was not Gα i/o -dependent. Table 2 . In principle, it is problematic to interpret differences in ligand potencies between different assays systems, assessing different functional readouts. While different potencies might indeed reflect agonist bias, they might also be due to different coupling efficacies of the target receptor to the respective effectors, or simply to differences in parameters that determine the sensitivity of a given assay. However, the relative comparison of EC 50 s obtained for a set of ligands with respect to a reference ligand permits to draw conclusions on their respective set of relative potencies. Moreover, the reconstituted systems used in this study are similar with respect to the expressed quantities of the transfected receptor, ß-arrestin, and Gα i1 ( Supplementary Figs. 1 and 2, Supplementary Table 1) . Therefore, as a prospective limitation, our study does not address physiological or pathophysiological conditions of primary cells, which may be different from our model system due to availability of the respective signaling molecules.
Potency of EP
Overall, the observed potency of all ligands for cAMP generation was greater than for ß-arrestin recruitment, except for PGE 1 alcohol, for which no significant difference of pEC 50 values was observed between these two assays ( (Fig. 5A ). Six out of the ten ligands had a relative bias towards ß-arrestin recruitment over Gα s compared to PGE 2 , with PGE 1 alcohol as the most ß-arrestin-biased agonist (Fig. 5B) . PGE 1 alcohol was also the only ligand that had an arrestin over Gα i1 bias (Fig. 5C ).
Intrinsic activity of EP 4 ligands for Gα s , Gα i1 and ß-arrestin 2 signaling pathways.
We then compared the relative intrinsic activities of the different ligands in Gα s , Gα i1 and ß-arrestin 2 signaling pathways (Table 1) , using PGE 2 as a reference "full agonist" set at 100%.
Most ligands proved to be full agonists for the three pathways tested. One exception was PGD 2 , which was a partial agonist for recruitment of ß-arrestin 2 (intrinsic activity of 77.9 ± 4.4%; Table 1 , Fig. 6 ), but a full agonist for activation of Gα s and Gα i1 pathways (93.2 ± 4.2% and 96.1 ± 1.6%, respectively). Inversely, L-902688 had (slightly) lower intrinsic activity in cAMP production and the Gα i1 pathway (94.4 ± 2.6% and 89.9 ± 2%, respectively), while being full agonist for ß-arrestin (102.6 ±1.1%).
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Discussion
During the past years, it became increasingly clear that G-protein coupled receptors can activate independently a variety of signaling effectors, and that distinct receptor ligands can do so with different potencies and efficacies (intrinsic activities). This selective activation of independent pathways by ligands has been termed functional selectivity (Urban et al., 2007) . The conceptual basis for this is that GPCRs do not have merely "inactive" and "active"
conformations, but that ligands can stabilize distinct receptor conformations, which are more or less potent and efficient in activating a given readout (Kenakin, 2003; Kenakin, 2007) . The significance of functional selectivity obviously raises the question whether previously reported properties of synthetic or natural ligands were based on the "right" (that is, clinically relevant) readout, especially for compounds that have therapeutic use. Moreover, for most clinical contexts the relevant signaling pathway of any given receptor remains often as yet elusive (Bosier and Hermans, 2007) . Experiments using synthetic ligands with known functional selectivity profiles in animal models will be required to pin down the clinically relevant receptor signaling pathways, and might also identify drug candidates or leads for further development. However, functional selectivity profiles of drugs and synthetic ligands are only beginning to be identified (Galandrin and Bouvier, 2006; Audet et al., 2008; Gao and Jacobson, 2008; Masri et al., 2008) .
Reassessment of ligand-induced signaling activity of known GPCR ligands is therefore
warranted, taking functional selectivity into account.
Classically, the prostaglandin receptor EP 4 had been classified as coupling to the Gα s subunit as an effector. However, in recent years, EP 4 signaling has revealed more complex and was shown to also involve coupling to PTX-sensitive Gα i proteins as well as ß-arrestin mediated effects. Importantly, ß-arrestin recruitment to EP 4 rather than Gα s -mediated signaling has been This article has not been copyedited and formatted. The final version may differ from this version. was a relatively weak activator of ß-arrestin recruitment, but a relatively better activator of Gα i1 than PGE 2 (Fig. 5) . The order of potency for PGE 1 alcohol and PGF2α, PGD 2 or M&B28767 was reversed for ß-arrestin recruitment and Gα i1 activation: PGE 1 alcohol was more potent for the ß-arrestin pathway than for the Gα i1 pathway, while the opposite was true for PGF 2α , PGD 2 and M&B28767 ( Fig. 4A , Table 1 ). This reversal of potency ratio for these signaling pathways is incompatible with a single receptor active state, but in line with the existence of ligand-specific receptor states that result in differential activation of signaling pathways, as suggested by the concept of functional selectivity (Urban et al., 2007) .
Interestingly, we observed that most agonists tested had full intrinsic activity in all pathways, as reported earlier for cAMP production (Wilson et al., 2004 ). An exception was L-902688 that had slightly but significantly reduced efficacy in activation of both tested G-proteins.
PGD 2 was also less efficacious in ß-arrestin recruitment as detected by BRET. It is important to consider that maximal responses from BRET assays may relate to either more interacting molecules or to closer donor-acceptor distances. In this case, lower intrinsic activity for ß-arrestin/EP 4 BRET induced by PGD 2 as compared to the reference ligand PGE 2 thus suggests that either less arrestin molecules are recruited to the receptor-fused energy acceptor, or that the energy transfer is less efficient in the receptor/arrestin complex induced by PGD 2 due to distinct conformational changes. Indeed, recently reported results obtained with the angiotensin receptor AT1aR, the ß2-adrenergic receptor, and the parathyroid hormone receptor type 1 (PTH1R), revealed different arrestin conformations depending on the ligand that was applied (Shukla et al., 2008) . Accordingly, it might be expected that such different arrestin conformations also translate in different BRET between receptor and arrestin. We interpret the lower efficacy of L-902688 in the Gα i1 /Gβ 1 BRET as a distinct conformational rearrangement in the Gα i1 ß 1 γ 2 heterotrimer.
Indeed, the PGE 2 -induced BRET decrease between Gα i1 -Rluc and YFP-ß 1 could reflect dissociation of α i1 from the ß 1 γ 2 dimer, but overall results obtained by Galés et al. (2006) strongly suggest that this BRET variation rather corresponds to Gα i1 ß 1 γ 2 structural rearrangements within a stable heterotrimer that results in G-protein activation. This is, however, not true for the cAMP Epac BRET sensor, where signal intensity only relates to cAMP levels, and not to different conformations of the sensor.
The paucity of differences in intrinsic activity between ligands is in line with previous reports on these ligand's efficacies in cAMP production (Wilson et al., 2004) , but somewhat surprising when considering results obtained in other receptor systems. Indeed, large differences in ß-arrestin recruitment efficacy (also measured by BRET) were observed in studies with synthetic agonists of the dopamine D2 receptor (Klewe et al., 2008) or natural peptide agonists of the glucagon-like peptide receptor (Jorgensen et al., 2007) . We speculate that the relative stability in intrinsic efficacy that we observed might be linked to the structural similarity of the here employed ligands (Table 2 ). In principle, differences in intrinsic ligand activity might also be masked by receptor overexpression, leading to increased receptor reserve and underestimation of the maximal response. This clearly is not the case for the Epac-based cAMP assay where the maximal response lies within the dynamic response range as shown with a saturating concentration of forskolin. In the intermolecular BRET systems between Gα i1 ß 1 or EP 4 -ß-arrestin, in turn, maximal response cannot be evaluated, as they may depend on both quantitative and qualitative differences (see above).
This article has not been copyedited and formatted. The final version may differ from this version. The activation of the Gα i1 and ß-arrestin recruitment pathways by EP 4 has been reported much later than its responses in the classical Gα s pathway. Accordingly, our study is the first to systematically report these pathways for a series of EP 4 agonists. The finding that a substantial number of the tested ligands are relatively stronger activators of these non-canonical EP 4 pathways than the natural ligand PGE 2 must be taken into account when using these compounds as tools in experiments designed to further dissect the biological roles of EP 4 , for example in cancer genesis and progression.
Taken together, our study is the first to systematically characterize the response of a set of EP 4 agonists for the downstream effectors ß-arrestin and Gα i1 , using BRET-based methodology that should be applicable for the study of other GPCRs. We find significant functional selectivity among the studied ligands. While more work will be required to examine the bearing of our observations in a more complex native context including the presence of other PGE 2 receptors, our EP 4 -limited study is the first step for assessing the consequences of functional selectivity in physiology and drug treatment. Cells were exposed to increasing concentrations of agonist and BRET measured as described in methods to determine concentration-response effects on cAMP production, Gα i1 activation and ß- Misoprostol free acid 23 (Abramovitz et al., 2000) This article has not been copyedited and formatted. The final version may differ from this version. 
